





Drugs of Renal Block



Important Notes Extra

Renal Excretion



1-Glomerular filtration

Glomerular filtration occurs to :

➤ Low MW drugs. ➤ Only free drugs. ➤ Polar or ionized. e.g <u>aminoglycosides</u>

➤ Drugs with low volume of distribution.

2-Active tubular secretion

General characteristics of active tubular secretion include;

- 1-carrier mediated.
- 2- saturable.
- 3-Requires energy.
- 4-transports drugs against concentration gradients. 5-Non-specific.



Renal Excretion

Competition Between Drugs For Same Transporter

Beneficial Competition between Drugs

Harmful Competition between Drugs

Probenecid and Penicillin G

Probenecid and Nitrofurantoin

Passive or Active Tubular reabsorption

Only lipid soluble drugs are passively reabsorbed

Ionized drugs are poorly reabsorbed

Endogenous substances such as glucose, uric acid, electrolytes, amino acids, and vitamins are actively reabsorbed. Probenecid will inhibit the reabsorption of uric acid so is uricosuric drug.

Occurs in DCT and collecting ducts.

Factors Affecting Renal Excretion of Drugs

- Blood flow to the kidney
- Physiochemical properties of drugs
 - → Molecular weight
 - → Lipid solubility
 - → Degree of ionization
 - → Volume of distribution
 - → Binding character
- Biological factor e.g. age
- Disease states
- Urine pH

Renal Excretion

Urinary pH trapping (Ion trapping)

Urine is normally slightly acidic and favors excretion of basic drugs.

Urine acidification by ammonium chloride (NH4Cl) increases excretion of basic drugs. Urine alkalization by by sodium bicarbonate NaHCO3 increases excretion of acidic drugs.

NSAIDS e.g aspirin and ibuprofen inhibits the production of PGs and therefore reduces renal perfusion and GFR.

Orders of Elimination:		
Zero-order	First-order	
The half-life is At two places on the curve		
Not equal	equal	
Constant is lost per unit time		
Amount	Percentage	
The rate of excretion is		
rate of excretion is independent of the concentration of drugs in the plasma. The enzyme is saturated by a high free drug concentration, and the rate of elimination remains constant, even if the dosage is increased, this may increase toxicity of drugs.	rate of excretion is directly proportional with concentration of drug in plasma. if the dose is increased, the excretion rate is increased, (that is, with each half-life, the concentration decreases constantly by 50%)	
E.g . Ethanol(alcohol), phenytoin, aspirin	E.g. penicillin, aminoglycoside , quinolones	
What do we do in the case of renal impairement ? Drugs that are primarily excreted by the kidney need dose adjustment when creatinine		

clearance is below 60 ml/min. **Minor** dose adjustment if **CrCl = 30-60 mL/min. Major** dose adjustment if **CrCl < 15mL/min**. **Monitor blood levels** of drugs (therapeutic drug monitoring).

Drugs of Renal Block

Treatment of UTIs		
Drug	Key Points	Contraindicat ions
Co-trimoxazole	 Bactericidal. M.O.A: Sulfamethoxazole inhibits the incorporation of PABA into dihydrofolic acid precursors, and trimethoprim prevents reduction of dihydrofolate to tetrahydrofolate. ratio of TMP to SMX in vivo is 1:20 (formulated 5(SMX):1(TMP)* ADRS: Displace bilirubin (kernicterus) Biplace bilirubin (kernicterus) Biplace bilirubin (kernicterus) 	 -Renal or hepatic failure. -Pregnancy -Nursing mother -Infants < 6 weeks -Blood disorders
Nitrofurantoins	 Effective against E.coli & Staph. Saprophyticus. Urine turns to dark orange-brown (harmless). M.O.A: Sensitive bacteria reduce the drug to an active agent that inhibits various enzymes and damages DNA. Uses: It's usefulness is limited to lower UTI's & cannot be used for upper UT or systemic infections. Dose: 50-100mg, orally, 6h/7 days. Long acting: 100mg twice daily. ADRS: 1.GI disturbance(take with food to avoid Diarrhea) Hemolytic anemia (G6PD Deficiency). Headache and nystagmus 	-Patients with G6PD deficiency. -Neonates -Pregnancy
Doxycycline	 M.O.A: Inhibit protein synthesis by binding reversibly to 30s subunit Against gm+ve & gm- ve bacteria. given 100 mg orally twice daily Uses: 1. Treatment of UTIs due to Mycoplasma & Chlamydia. 2. Prostatitis. ADRS: 1. Thrombophlebitis - I.V. 2. Brown discolouration of teeth in children. 3. Deformity/growth inhibition of bones in children. 	-Pregnancy -Breast feeding -Children below 10 years

Drugs of Renal Block

Treatment of UTIs			
Drug	Key Points	Contraindicat ions	
Cephalosporins 3rd gen e.g ceftriaxone, Ceftazidime.	 Bactericidal. M.O.A: Inhibit bacterial cell wall synthesis. Uses: severe/complicated UTIs & acute prostatitis. ceftriaxone t1/2=4-7 hours, others very short 30-90 mins. ADRS: Hypersensitivity reactions. Thrombophlebitis. 	Renal or hepatic failure.	
Fluoroquinolones (<mark>Ciprofloxacin,</mark> Moxifloxacin and Gatifloxacin)	 M.O.A: Block bacterial DNA synthesis by inhibiting DNA Gyrase enzyme. Uses: 1. UTIs caused by multidrug resistance organism as pseudomonas. 2. Prostatitis (acute/chronic). gram -ve bacter ADRS: Arthropathy. Phototoxicity. 	-Not recommended for patients younger than 18 years -Pregnancy -Breastfeeding women	
Gentamicin	 Given I.M or I.V. poorly absorbed orally (highly charged). Active against gm-ve aerobic organisms. More active in alkaline medium. M.O.A: Inhibit protein synthesis by binding to 30S ribosomal subunits . <u>Similar to tetracyclines.</u> Uses: Severe infections caused by gram negative organism (pseudomonas or enterobacter). ADRS: Ototoxicity. 		

Drugs of Renal Block

Diuretics			
Drug	Key Point	Contra- indications	
Carbonic anhydrase inhibitors (in PCT, interferes with NaHCO3 re-absorption and causes diuresis)			
Dorzolamide	Used topically for treatment of open- angle glaucoma. No systemic ADRS or diuresis.		
Acetazolamide	 po, rapid onset, long duration of action Excreted by active secretion in PCT Produces alkaline urine and cause metabolic acidosis Mild ↑ in urine volume ↑ excretion of sodium, bicarbonate, potassium, phosphate. Therapeutic uses: As prophylactic therapy, in acute mountain sickness ↓ CSF of brain Formation of CSF (Useful in treating benign intracranial hypertension) Urinary alkalinization to enhance renal excretion of acidic substances Hyperphosphatemia Adjunct for treatment of epilepsy Metabolic alkalosis ADRs: Hypokalemia, Metabolic acidosis, Renal stone formation, Hypersensitivity reaction, CNS effects, tingling, numbness 	patient with liver cirrhosis	
Osmotic Diuretics (In PCT + descending loop)			
Mannitol	 Poorly absorbed by GI, given I.V, if given PO will cause osmotic diarrhea, Not metabolized - Excreted by glomerular filtration without being re-absorbed or secreted within 30-60 min ↑ urine output by osmosis Therapeutic uses: Acute renal failure due to shock or trauma acute drug poisoning maintain urine volume & prevent anuria resulting 	Chronic heart failure	

Drug	Key Point	Contraindications	
Cont. Osmotic Diuretics			
Mannitol	 To↓intracranial & intraocular pressure before ophthalmic or brain procedures (cerebral edema). ADRs: Headache, nausea, vomiting Extracellular volume expansion Excessive use will cause dehydration & hypernatraemia 		
	Loop diuretics		
Furosemide Torsemide Bumetanide Ethacrynic acid	M.O.A: Inhibit Na/K/2Cl co-transporter in the luminal membrane of the thick ascending loop of Henle &inhibit reabsorption of Ca&Mg -increase urinary excretion of Na/k/2cl and paracellularly Ca and Mg. -High natriuresis -Oral or IV -Emergency use -Excretion of <u>active</u> tubular secretion of weak acids into urine -USES: Edema associated w/ CHF & nephrotic syndrome- Acute hypercalcemia & acute hyperkalemia, Br, F, I toxicity ADRS: ototoxicity/metabolic alkalosis/allergic reactions	Drug-drug interactions: 1- NSAIDs: reduce diuretic response 2-digitalis: arrhythmia 3-aminoglycosides: increase ototoxicity	
Thiazide diuretics			
Chlorothiazide Hydrochlorothiaz ide Chlorthalidone Metolazone Indapamide	 -M.O.A: acts via inhibition of Na/Cl co- transporter on the luminal membrane of distal convoluted tubules. -P.K: moderate efficacy natriuresis & given orally. -Uses: essential hypertension, mild heart failure & edema,osteoporosis, Calcium nephrolithiasis, Nephrogenic diabetes insipidus. -ADRs: Fluid and electrolyte imbalance,Hyponatremia, Hypovolemia (volume depletion) Hypokalemia, Metabolic alkalosis, Hyperuricaemia (gout), Hypercalcemia, Hyperglycaemia & Hyperlipidemia. 	 Drug- drug interactions: 1- Uricosurics diminish Thiazide effect. 2-Thiazide increase Digitalis effect. 3- NSAIDs Reduce Thiazide efficacy 	

Drug	Key Point	Contraindications		
Potassium Sparing Diuretics				
Aldosterone Antagonists				
Spironolactone Eplerenone	 -act at the collecting duct by competitive inhibition of cytoplasmic aldosterone receptors ↑ urinary Na+ excretion ↓ urinary K+ excretion (Hyperkalemia) ↓ H+ excretion (acidosis) -has antiandrogenic action. Uses : -Treatment of hypertension combined with thiazide or loop diuretics to: -Enhance natriuresis caused by other diuretics - Correct for hypokalemia -Treatment of primary hyperaldosteronism (Conn's syndrome) -Treatment of secondary hyperaldosteronism in diseases as CHF, Edema of hepatic cirrhosis(drug of choice), Nephrotic syndrome. -Treatment of hirsutism, acne due to the antiandrogenic effects. ADRS: Hyperkalaemia,Metabolic acidosis,Gynecomastia ,Impotence,Menstrual irregularities,GIT upset and peptic ulcer. 	 -Hyperkalaemia: → chronic renal failure → K+ supplement use* → β-blockers* → ACE inhibitors*. -Liver disease (dose adjustment is needed) Digitalis-Spironolactone alters it's clearance Salicylates-decrease efficacy and secretion. *Drug-Drug Interaction Because it will lead to ↑ Hyperkalemia induced by K-Sparing diuretics 		
	Na+ Channels Inhibitors			
Amiloride Triamterene	 -Inhibition of Na influx through directly blockade of the epithelial sodium channel epithelial sodium channel (ENaC) on the lumen side of the kidney collecting tubule. Uses: -Used in Combination with Loop & Thiazide Diuretics -Treatment for lithium-Induced Diabetes Insipidus. ADRS: -Hyperkalemia 	in patients who are also on -ACE inhibitors, - angiotensin II receptor antagonists -other potassium sparing diuretics - potassium-containing supplements.		



"It is not hard, you just made it to the end!"

Team Leaders:



Thanks for those who worked on this lecture:

Adel Alsuhaibani Abdullah Almoaither Faisal Alhawtan Nouf Al Otaibi Dimah Al Araifi Ghaida Al Sanad Fatimah Al Bassam

References:

 \checkmark Doctors' notes and slides



@Pharma4370



pharmacology437@gmail.com